| FAQ/Help |
| Calendar |
| Search |
| Today's Posts |
07-11-2016, 06:11 PM
|
#1 | ||
|
|||
|
Member
|
Herantis Pharma announced that a pipeline therapy known as cerebral dopamine neurotrophic factor (CDNF) has been granted Orphan Drug Status by the FDA to speed its development and testing as a potential treatment for ALS and Parkinson’s disease. CDNF is a neuroprotective and neurotrophic protein that has shown potential for the regeneration and protection of dopamine-generating neurons, cells involved in Parkinson’s pathology.
This is a very interesting treatment as it appears to be conceptually similar to Genervon's GM6 (MNTF), which had successful Phase 2a trials with both PD and ALS patients. Unfortunately, Genervon is under-funded and is moving slowly with a larger Phase 2 trial. They are concentrating at this time on getting approval as an ALS treatment. Potential Treatment for ALS Marked by FDA for Speedy Development Last edited by Tupelo3; 07-12-2016 at 07:09 AM. |
||
|
 Reply With Quote
|
| "Thanks for this!" says: | anagirl (07-12-2016), badboy99 (07-12-2016), eds195 (07-11-2016), GerryW (07-11-2016), johnt (07-11-2016), olsen (07-12-2016), rainbow676 (07-12-2016), RLSmi (07-11-2016), soccertese (07-11-2016) |
| Reply |
|
|
Similar Threads
|
||||
| Thread | Forum | |||
| FDA Grants “Orphan Drug” Status for Genervon’s Multi-Target ALS and PD Drug GM604 | Parkinson's Disease | |||
| Cogane™ Granted Orphan Drug Status for Treatment of ALS | Parkinson's Disease | |||
| CoQ10/UBIQUINONE RECEIVES ORPHAN DRUG STATUS | Parkinson's Disease | |||
FDA Grants Orphan Drug Status to Potential ALS and Parkinson's Treatment - CDNF
Linear Mode
